AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...
AbbVie has acknowledged that 2024 will be a nadir revenues-wise, with a return to growth due in 2025. At one point Humira (adalimumab) pulled in more than $20 billion a year, but the brand ...
Class will soon be in session at the Allergan Aesthetics headquarters. The AbbVie brand plans to open doors at its ...
AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback